Telix Pharmaceuticals
- Short interest
- 10.71%
- +0.18 pp 30d
- as of 8 Oct 2026
- Reported shorts
- 36.5M
- Shares on issue
- 340.330M
Telix Pharmaceuticals (TLX) Short Interest
Telix Pharmaceuticals (ASX:TLX) had 10.71% of shares reported as short positions as of 8 Oct 2026, representing 36,464,140 shares. Telix Pharmaceuticals operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Telix Pharmaceuticals
Telix Pharmaceuticals is a global biopharmaceutical company specializing in the development and commercialization of radiopharmaceuticals for cancer treatment. The company focuses on precision oncology, utilizing targeted radiation to treat urologic, neurologic, and musculoskeletal cancers. Telix's unique value lies in its ability to deliver focused radiation doses with precision targeting, minimizing damage to healthy tissues.
Company profile →Telix Pharmaceuticals (ASX:TLX) has 10.71% of its shares on issue reported as short positions as of 8 Oct 2026, or about 36,464,140 shares. Over the past 30 days that figure has risen 0.18 percentage points, and over 90 days it has fallen 1.14 percentage points. Its highest recorded short interest was 16.51% in April 2026. TLX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads TLX today
- Zanger BreakoutWatchScore 44rank 151 of 1931
- CAN SLIMWatchScore 18rank 759 of 1541
- Minervini Trend TemplateSetupScore 55rank 110 of 1736
- Crowded-Short BreakoutSetupScore 46rank 22 of 1479
- Quality compoundersWatchScore 33rank 346 of 1677
Prices to 13 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
TLX fundamentals
In the year to 31 Dec 2025, Telix Pharmaceuticals (ASX:TLX) recorded revenue of US$803.8M and a net loss after tax of US$7.1M. A year earlier it recorded revenue of US$516.6M and net profit after tax of US$33.7M. Year-on-year growth: revenue +55.6% (FY). Net margin −0.9% (FY). Figures are in USD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest TLX news
All news- Why Is Telix Pharmaceuticals (ASX:TLX) Back in Focus?
kalkine · 14 Oct 2026
- First U.S. Brain Scan Doses Could Be A Game Changer For Telix Pharmaceuticals (ASX:TLX) - Simply Wall Street
googlenews · 13 Oct 2026
- Why Telix Pharmaceuticals (ASX:TLX) Is Now Judged on Profit and Regulatory Decisions in the ASX 200 - Kalkine
googlenews · 8 Oct 2026
Company details
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss TLX
Start a research thread or post the first pulse update